Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 426 across all filing types
Latest filing 2024-04-09 Annual Report
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Annual report 2023
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Arctic Bioscience for the fiscal year 2023. It includes a table of contents, a letter from the CEO, key financial figures (Income Statement, Balance Sheet, Cash Flow), management reports, and an independent auditor's report. This aligns with the definition of a 10-K or Annual Report. FY 2023
2024-04-09 English
Arctic Bioscience - Annual report 2023
Report Publication Announcement Classification · 99% confidence The document explicitly states it is the 'Arctic Bioscience - Annual report 2023' and mentions it includes the 'Board of Directors report and financial statements'. However, the document is very short (1549 characters) and its primary function, based on the text, is to announce that the Annual Report 'is attached to this stock notice and is available on the company's website.' According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is attached or published should be classified as a Report Publication Announcement (RPA), rather than the full Annual Report (10-K). Although the content describes an Annual Report, the format is that of a publication announcement.
2024-04-09 English
Arctic Bioscience - Årsrapport 2023
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Arctic Bioscience for the fiscal year 2023. It includes a table of contents, a letter from the CEO, key financial figures (Income Statement, Balance Sheet, Cash Flow), management reports, and an independent auditor's report. This aligns with the definition of a 10-K or Annual Report. FY 2023
2024-04-09 English
Arctic Bioscience - Årsrapport 2023
Report Publication Announcement Classification · 99% confidence The document is titled "Arctic Bioscience - Årsrapport 2023" (Annual Report 2023) and explicitly states that the company has published its annual report, including the board's annual review and financial statements. However, the document text itself is very short (1429 characters) and primarily serves as an announcement, stating: "Rapporten er vedlagt børsmeldingen og er tilgjengelig på selskapets hjemmesider" (The report is attached to the stock exchange announcement and is available on the company's website). According to Rule #2 (The 'MENU VS MEAL' Rule), when a short document announces the publication of a full report (like an Annual Report), it should be classified as a Report Publication Announcement (RPA). Although the content relates to the Annual Report (10-K), the format is that of an announcement of publication.
2024-04-09 Norwegian
Arctic Bioscience - Extension of share options to members of management group
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving 'person discharging managerial responsibilities' (insiders) and the issuer, Arctic Bioscience AS. Specifically, it reports the 'Acceptance of share options' and 'Share Purchase' by executives (EVP, CTO) on specific dates (2024-03-15). This pattern perfectly matches the definition of Director's Dealing, which covers personal share transactions by company directors and executives.
2024-03-15 English
Arctic Bioscience - Forlengelse av aksjeopsjoner til medlemmer av ledergruppen
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving 'person discharging managerial responsibilities' (insiders) and the issuer, Arctic Bioscience AS. Specifically, it reports the 'Acceptance of share options' and 'Share Purchase' by executives (EVP, CTO) on specific dates (2024-03-15). This pattern perfectly matches the definition of Director's Dealing, which covers personal share transactions by company directors and executives.
2024-03-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.